{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T06:49:28Z","timestamp":1765176568737,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>How to address the counseling of lifetime risk of developing Parkinson\u2019s disease in patients with Gaucher disease and their family members carrying a single variant of the <jats:italic>GBA1<\/jats:italic> gene is not yet clearly defined. In addition, there is no set way of managing Gaucher disease patients, taking into account the possibility that they may show features of Parkinson\u2019s disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Starting from an overview on what has recently changed in our knowledge on this issue and grouping the experiences of healthcare providers of Gaucher disease patients, we outline a path of counseling and management of Parkinson\u2019s disease risk in Gaucher disease patients and their relatives.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The approach proposed here will help healthcare providers to communicate Parkinson\u2019s disease risk to their patients and will reduce the possibility of patients receiving inaccurate information from inadequate sources. Furthermore, this resource will help to empower healthcare providers to identify early signs and\/or symptoms of Parkinson\u2019s disease and decide when to refer these patients to the neurologist for appropriate specific therapy and follow-up.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-020-01529-y","type":"journal-article","created":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T11:03:39Z","timestamp":1600859019000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Parkinson\u2019s disease in Gaucher disease patients: what\u2019s changing in the counseling and management of patients and their relatives?"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9677-880X","authenticated-orcid":false,"given":"Maja","family":"Di Rocco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Di Fonzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Barbato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Domenica","family":"Cappellini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Carubbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiorina","family":"Giona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano","family":"Giuffrida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Linari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Pession","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Quarta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Spada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Strisciuglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Generoso","family":"Andria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,23]]},"reference":[{"key":"1529_CR1","volume-title":"GeneReviews\u00ae","author":"GM Pastores","year":"1993","unstructured":"Pastores GM, Hughes DA. Gaucher disease 2000 Jul 27 [updated 2018 Jun 21]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, LJH B, Stephens K, Amemiya A, editors. GeneReviews\u00ae. Seattle: University of Washington, Seattle; 1993\u20132020."},{"issue":"2","key":"1529_CR2","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3390\/ijms18020441","volume":"18","author":"J Stirnemann","year":"2017","unstructured":"Stirnemann J, Belmatoug N, Camou F, et al. A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci. 2017;18(2):441\u201370.","journal-title":"Int J Mol Sci"},{"key":"1529_CR3","doi-asserted-by":"publisher","unstructured":"Schiffmann R, Sevigny J, Rolfs A, et al. The definition of neuronopathic Gaucher disease. J Inherit Metab Dis. 2020:1\u20134 https:\/\/doi.org\/10.1002\/jimd.12235.","DOI":"10.1002\/jimd.12235"},{"issue":"2","key":"1529_CR4","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/S1096-7192(03)00071-4","volume":"79","author":"N Tayebi","year":"2003","unstructured":"Tayebi N, Walker J, Stubblefield B. Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab. 2003;79(2):104\u20139.","journal-title":"Mol Genet Metab"},{"key":"1529_CR5","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/B978-0-444-59565-2.00040-X","volume":"133","author":"C Mignot","year":"2013","unstructured":"Mignot C, Gelot A, Bilette de Villemeur T. Gaucher disease. Handb Clin Neurol. 2013;133:1709\u201315.","journal-title":"Handb Clin Neurol"},{"issue":"3","key":"1529_CR6","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/BF03159935","volume":"14","author":"KA Jellinger","year":"1991","unstructured":"Jellinger KA. Pathology of Parkinson\u2019s disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol. 1991;14(3):153\u201397.","journal-title":"Mol Chem Neuropathol"},{"key":"1529_CR7","first-page":"15","volume":"46","author":"H Braak","year":"1995","unstructured":"Braak H, Braak E, Yilmazer D, Schultz C, de Vos RA, Jansen EN. Nigral and extranigral pathology in Parkinson\u2019s disease. J Neural Transm Suppl. 1995;46:15\u201331.","journal-title":"J Neural Transm Suppl"},{"issue":"4","key":"1529_CR8","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","volume":"79","author":"J Jankovic","year":"2008","unstructured":"Jankovic J. Parkinson\u2019s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368\u201376.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1529_CR9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/nrneurol.2017.157","volume":"14","author":"B H\u00f6gl","year":"2018","unstructured":"H\u00f6gl B, Stefani A, Videnovic A, et al. Idiopathic REM sleep behaviour disorder and neurodegeneration-an update. Nat Rev Neurol. 2018;14(1):40\u201355.","journal-title":"Nat Rev Neurol"},{"issue":"9","key":"1529_CR10","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/qjmed\/89.9.691","volume":"89","author":"O Neudorfer","year":"1996","unstructured":"Neudorfer O, Giladi N, Elstein D, et al. Occurrence of Parkinson\u2019s syndrome in type 1 Gaucher disease. QJM. 1996;89(9):691\u20134.","journal-title":"QJM"},{"issue":"12","key":"1529_CR11","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1136\/jmg.2004.024455","volume":"41","author":"O Goker-Alpan","year":"2004","unstructured":"Goker-Alpan O, Schiffmann R, LaMarca ME, et al. Parkinsonism among Gaucher disease carriers. J Med Genet. 2004;41(12):937\u201340.","journal-title":"J Med Genet"},{"key":"1529_CR12","doi-asserted-by":"publisher","first-page":"a00888813","DOI":"10.1101\/cshperspect.a008888","volume":"2","author":"C Klein","year":"2012","unstructured":"Klein C, Westenberger A. Genetics of Parkinson\u2019s disease. Cold Spring Harb Perspect Med. 2012;2:a00888813.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"1529_CR13","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3390\/cells8040364","volume":"8","author":"GM Riboldi","year":"2019","unstructured":"Riboldi GM, Di Fonzo AB. GBA1, Gaucher disease, and Parkinson\u2019s disease: from genetic to clinic to new therapeutic approaches. Cells. 2019;8(4):364. https:\/\/doi.org\/10.3390\/cells8040364.","journal-title":"Cells."},{"issue":"17","key":"1529_CR14","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky E, Nalls J, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease. N Engl J Med. 2009;361(17):1651\u201361.","journal-title":"N Engl J Med"},{"key":"1529_CR15","first-page":"3136415","volume":"2018","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Shu L, Zhou X, et al. A meta-analysis of GBA1 related clinical symptoms in Parkinson\u2019s disease. Parkinsons Dis. 2018;2018:3136415.","journal-title":"Parkinsons Dis"},{"issue":"24","key":"1529_CR16","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1212\/01.wnl.0000304039.11891.29","volume":"70","author":"Z Gan-Or","year":"2008","unstructured":"Gan-Or Z, Giladi N, Rozovski U, et al. Genotype-phenotype correlations between GBA1 mutations and Parkinson\u2019s disease risk and onset. Neurology. 2008;70(24):2277\u201383.","journal-title":"Neurology"},{"issue":"5","key":"1529_CR17","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/ana.24777","volume":"80","author":"R Cilia","year":"2016","unstructured":"Cilia R, Tunesi S, Marotta G, et al. Survival and dementia in GBA1 associated Parkinson\u2019s disease: the mutation matters. Ann Neurol. 2016;80(5):662\u201373.","journal-title":"Ann Neurol"},{"issue":"1","key":"1529_CR18","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13024-019-0336-2","volume":"14","author":"J Do","year":"2019","unstructured":"Do J, McKinney C, Sharma P, Sidransky E. Glucocerebrosidase and its relevance to Parkinson disease. Mol Neurodegener. 2019;14(1):36.","journal-title":"Mol Neurodegener"},{"issue":"12","key":"1529_CR19","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1093\/brain\/awx285","volume":"140","author":"LA Robak","year":"2017","unstructured":"Robak LA, Jansen IE, van Rooij J, et al. Excessive burden of lysosomal storage disorder gene variants in Parkinson\u2019s disease. Brain. 2017;140(12):3191\u2013203.","journal-title":"Brain."},{"issue":"8","key":"1529_CR20","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1136\/jnnp-2012-302402","volume":"83","author":"A McNeill","year":"2012","unstructured":"McNeill A, Duran R, Hughes DA, Mehta A, Schapira AH. A clinical and family history study of Parkinson\u2019s disease in heterozygous glucocerebrosidase mutation carriers. J Neurol Neurosurg Psychiatry. 2012;83(8):853\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1529_CR21","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/jgc4.1185","volume":"29","author":"L Zaretsky","year":"2020","unstructured":"Zaretsky L, Zeid N, Naik H, Roy N, Alcalay RN, Balwani M. Knowledge and attitudes of Parkinson\u2019s disease risk in the Gaucher population. J Genet Couns. 2020;29(1):105\u201311.","journal-title":"J Genet Couns"},{"issue":"6","key":"1529_CR22","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s10897-017-0123-6","volume":"26","author":"L Cook","year":"2017","unstructured":"Cook L, Schulze J. Connecting Gaucher and Parkinson disease: considerations for clinical and research genetic counseling settings. J Genet Couns. 2017;26(6):1165\u201372.","journal-title":"J Genet Couns"},{"key":"1529_CR23","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s10897-017-0161-0","volume":"27","author":"M Mulhern","year":"2018","unstructured":"Mulhern M, Alcalay RN, Balwani M. Patients\u2019 opinions on genetic counseling on the increased risk of Parkinson disease among Gaucher disease carriers. J Genet Couns. 2018;27:675\u201380.","journal-title":"J Genet Couns"},{"key":"1529_CR24","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1136\/jnnp-2019-320394","volume":"90","author":"M Avenali","year":"2019","unstructured":"Avenali M, Toffoli M, Mullin S, et al. Evolution of prodromal parkinsonian features in a cohort of GBA mutation-positive individuals: a 6-year longitudinal study. J Neurol Neurosurg Psychiatry. 2019;90:1091\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"1529_CR25","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1002\/mds.27775","volume":"34","author":"S Mullin","year":"2019","unstructured":"Mullin S, Beavan M, Bestwick J, et al. Evolution and clustering of prodromal parkinsonian features in GBA1 carriers. Mov Disord. 2019;34(9):1365\u201373.","journal-title":"Mov Disord"},{"key":"1529_CR26","doi-asserted-by":"publisher","unstructured":"Petrucci S, Ginevrino M, Trezzi I, et al. GBA- related Parkinson\u2019s disease: dissection of genotype-phenotype correlates in a large Italian cohort. Mov Disord. 2020. https:\/\/doi.org\/10.1002\/mds.28195.","DOI":"10.1002\/mds.28195"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01529-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-020-01529-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01529-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T23:14:41Z","timestamp":1632352481000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01529-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,23]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1529"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01529-y","relation":{},"ISSN":["1750-1172"],"issn-type":[{"type":"electronic","value":"1750-1172"}],"subject":[],"published":{"date-parts":[[2020,9,23]]},"assertion":[{"value":"12 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MDR has received travel support and honoraria from Sanofi Genzyme and Takeda (former Shire HGT). ADF has received travel support and honoraria from Sanofi Genzyme. AB has received travel support and honoraria from Sanofi Genzyme and Takeda (former Shire HGT). MDC is a member of advisory board for Vifor, Sanofi Genzyme, Celgene, Novartis and Bluebird, Vifor, Sanofi-Genzyme, Celgene, Novartis, Bluebird and Alnylam. FC has received fees for consultancy or lectures from Sanofi Genzyme and Takeda (former Shire HCT). FG has received travel support and educational grants from Sanofi Genzyme and Takeda (former Shire HGT). GG has received travel support and honoraria from Sanofi Genzyme. SL has received travel support and honoraria from Sanofi Genzyme and Takeda (former Shire HGT). AP has received travel support and honoraria from Sanofi Genzyme. AQ has received travel support and honoraria from Sanofi Genzyme. MS has received travel support and honoraria from Sanofi Genzyme. MS has received travel support and honoraria from Sanofi Genzyme. PS has received travel support and honoraria from Sanofi Genzyme. GA has received travel support and honoraria from Sanofi Genzyme.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"262"}}